Precision Medicine in Cholangiocarcinoma: Past, Present, and Future

Cholangiocarcinoma (CCA), or biliary tract cancer, has a poor prognosis. The median survival time among patients with CCA is under 2 years from diagnosis, and the global 5-year survival rate is only 10%. First-line therapy with chemotherapeutic agents, gemcitabine plus cisplatin, has traditionally b...

Descripción completa

Detalles Bibliográficos
Autores principales: Cheng, Chi-Yuan, Chen, Chiao-Ping, Wu, Chiao-En
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9225212/
https://www.ncbi.nlm.nih.gov/pubmed/35743860
http://dx.doi.org/10.3390/life12060829

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9225212/
https://www.ncbi.nlm.nih.gov/pubmed/35743860
http://dx.doi.org/10.3390/life12060829

Ejemplares similares